Skip to content

house · Committee report

H. Rept. 119-333

NANCY GARDNER SEWELL MEDICARE MULTI-CANCER EARLY DETECTION SCREENING COVERAGE ACT

2025-10-03

Committees

Associated legislation

Text

Background

H.R. 842 was introduced on January 31, 2025, and was referred to the Committee on Ways and Means and the Committee on Energy and Commerce. Committee Hearings The Committee on Ways and Means held the following hearing concerning the policy in H.R. 842: On February 11, 2025, the Committee on Ways and Means Health Subcommittee held a hearing titled, ``Modernizing American Health Care: Creating Healthy Options and Better Incentives'' to examine opportunities to improve preventive care within the United States. The hearing explored the lack of coverage for multi-cancer early detection screening tests within Medicare.

Committee Action

The Committee on Ways and Means marked up H.R. 842, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, on September 17, 2025, and favorably reported the bill, as amended, to the House of Representatives (with a quorum being present). D. Designated Hearing Pursuant to clause 3(c)(6) of rule XIII, the following hearing was used to develop and consider H.R. 842: ``Modernizing American Health Care: Creating Healthy Options and Better Incentives,'' on February 11, 2025. II. EXPLANATION OF THE BILL A. Reasons for Change The Committee on Ways and Means' reason for change is to provide Medicare coverage of multi-cancer early detection screening tests. B. Explanation of Provisions Section 1. Short Title The short title is ``Nancy Gardner Sewell Medicare Multi- Cancer Early Detection Screening Coverage Act''. Section 2. Medicare Coverage of Multi-Cancer Early Detection Screening Tests This provision provides temporary Medicare coverage of multi-cancer early detection screening tests to seniors aged 65 once a year and maintains that coverage through their lifetime in the program. In the case the United States Preventive Services Task Force issues an ``A'' or ``B'' rating, then the temporary coverage is removed and Medicare undertakes its normal coverage process. C. Effective Date The bill, as amended, would become effective January 1, 2029. III. VOTES OF THE COMMITTEE In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 842, the ``Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act,'' on September 17, 2025. H.R. 842 was ordered favorably reported to the House of Representatives as amended by a roll call vote of 43 yeas to 0 nays (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. X ...... ......... Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... X ...... ......... Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... X ...... ......... Mr. Larson........... X ...... ......... Mr. Schweikert..................... X ...... ......... Mr. Davis............ X ...... ......... Mr. LaHood......................... X ...... ......... Ms. Sanchez.......... ...... ...... ......... Mr. Arrington...................... X ...... ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... X ...... ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ X ...... ......... Ms. Chu.............. X ...... ......... Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... ......... Mrs. Miller........................ X ...... ......... Mr. Boyle............ X ...... ......... Dr. Murphy......................... X ...... ......... Mr. Beyer............ X ...... ......... Mr. Kustoff........................ X ...... ......... Mr. Evans............ X ...... ......... Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ X ...... ......... Mr. Steube......................... X ...... ......... Mr. Panetta.......... X ...... ......... Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... X ...... ......... Mr. Horsford......... ...... ...... ......... Mr. Moore.......................... X ...... ......... Ms. Plaskett......... X ...... ......... Ms. Van Duyne...................... X ...... ......... Mr. Suozzi........... X ...... ......... Mr. Feenstra....................... X ...... ......... Ms. Malliotakis.................... X ...... ......... Mr. Carey.......................... X ...... ......... Mr. Yakym.......................... X ...... ......... Mr. Miller......................... X ...... ......... Mr. Bean........................... X ...... ......... Mr. Moran.......................... X ...... ......... ---------------------------------------------------------------------------------------------------------------- IV. BUDGET EFFECTS OF THE BILL A. Committee Estimate of Budgetary Effects With respect to clause 3(d) of rule XIII of the Rules of the House of Representatives, a cost estimate provided by the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not made available to the Committee in time for the filing of this report. B. Statement Regarding New Budget Authority and Tax Expenditures Budget Authority In compliance with clause 3(c)(2) of rule XIII of the Rules of the House of Representatives, the Committee states that the bill involved no new or increased budget authority. The Committee states further that the bill involves no new or increased tax expenditures. C. Cost Estimate Prepared by the Congressional Budget Office With respect to the requirements of clause 3(c)(2) of rule XIII of the Rules of the House of Representatives and section 308(a) of the Congressional Budget Act of 1974 and with respect to requirements of clause (3)(c)(3) of rule XIII of the Rules of the House of Representatives and section 402 of the Congressional Budget Act of 1974, the Committee has requested but not received a cost estimate for this bill from the Director of Congressional Budget Office. The Chairman of the Committee shall cause such estimate and statement to be printed in the Congressional Record upon its receipt by the Committee. V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE A. Committee Oversight Findings and Recommendations With respect to clause 3(c)(1) of rule XIII of the Rules of the House of Representatives, the Committee made findings and recommendations that are reflected in this report. B. Statement of General Performance Goals and Objectives With respect to clause 3(c)(4) of rule XIII of the Rules of the House of Representatives, the Committee advises that the bill does not authorize funding, so no statement of general performance goals and objectives is required. C. Information Relating to Unfunded Mandates This information is provided in accordance with section 423 of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104- 4). The Committee has determined that the bill does not contain Federal mandates on the private sector. The Committee has determined that the bill does not impose a Federal intergovernmental mandate on State, local, or tribal governments. D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff Benefits With respect to clause 9 of rule XXI of the Rules of the House of Representatives, the Committee has carefully reviewed the provisions of the bill, and states that the provisions of the bill do not contain any congressional earmarks, limited tax benefits, or limited tariff benefits within the meaning of the rule. E. Duplication of Federal Programs In compliance with clause 3(c)(5) of rule XIII of the Rules of the House of Representatives, the Committee states that no provision of the bill establishes or reauthorizes: (1) a program of the Federal Government known to be duplicative of another Federal program; (2) a program included in any report from the Government Accountability Office to Congress pursuant to section 21 of Public Law 111-139; or (3) a program related to a program identified in the most recent Catalog of Federal Domestic Assistance, published pursuant to the Federal Program Information Act (Pub. L. No. 95-220, as amended by Pub. L. No. 98-169). VI. CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): SOCIAL SECURITY ACT * * * * * * * TITLE XVIII--HEALTH INSURANCE FOR THE AGED AND DISABLED * * * * * * * Part B--Supplementary Medical Insurance Benefits for the Aged and Disabled * * * * * * * PAYMENT OF BENEFITS Sec. 1833. (a) Except as provided in section 1876, and subject to the succeeding provisions of this section, there shall be paid from the Federal Supplementary Medical Insurance Trust Fund, in the case of each individual who is covered under the insurance program established by this part and incurs expenses for services with respect to which benefits are payable under this part, amounts equal to--(1) in the case of services described in section 1832(a)(1)--80 percent of the reasonable charges for the services; except that (A) an organization which provides medical and other health services (or arranges for their availability) on a prepayment basis (and either is sponsored by a union or employer, or does not provide, or arrange for the provision of, any inpatient hospital services) may elect to be paid 80 percent of the reasonable cost of services for which payment may be made under this part on behalf of individuals enrolled in such organization in lieu of 80 percent of the reasonable charges for such services if the organization undertakes to charge such individuals no more than 20 percent of such reasonable cost plus any amounts payable by them as a result of subsection (b), (B) with respect to items and services described in section 1861(s)(10)(A), the amounts paid shall be 100 percent of the reasonable charges for such items and services, (C) with respect to expenses incurred for those physicians' services for which payment may be made under this part that are described in section 1862(a)(4), the amounts paid shall be subject to such limitations as may be prescribed by regulations, (D) with respect to clinical diagnostic laboratory tests for which payment is made under this part (i)(I) on the basis of a fee schedule under subsection (h)(1) (for tests furnished before January 1, 2017) or [section 1834(d)(1)] subsection (d)(1) or (aa) of section 1834, the amount paid shall be equal to 80 percent (or 100 percent, in the case of such tests for which payment is made on an assignment-related basis) of the lesser of the amount determined under such fee schedule, the limitation amount for that test determined under subsection (h)(4)(B), or the amount of the charges billed for the tests, or (II) under section 1834A (for tests furnished on or after January1, 2017), the amount paid shall be equal to 80 percent(or 100 percent, in the case of such tests for which payment is made on an assignment-related basis) of the lesser of the amount determined under such section or the amount of the charges billed for the tests, or (ii) for tests furnished before January 1, 2017,on the basis of a negotiated rate established under subsection (h)(6), the amount paid shall be equal to 100 percent of such negotiated rate,,(E) with respect to services furnished to individuals who have been determined to have end stage renal disease, the amounts paid shall be determined subject to the provisions of section 1881,(F) with respect to clinical social worker services under section 1861(s)(2)(N), the amounts paid shall be 80 percent of the lesser of (i) the actual charge for the services or (ii) 75 percent of the amount determined for payment of a psychologist under clause (L), (G) with respect to facility services furnished in connection with a surgical procedure specified pursuant to subsection (i)(1)(A) and furnished to an individual in an ambulatory surgical center described in such subsection, for services furnished beginning with the implementation date of a revised payment system for such services in such facilities specified in subsection (i)(2)(D), the amounts paid, subject to subsection (i)(9), shall be 80 percent of the lesser of the actual charge for the services or the amount determined by the Secretary under such revised payment system, (H) with respect to services of a certified registered nurse anesthetist under section 1861(s)(11), the amounts paid shall be 80 percent of the least of the actual charge, the prevailing charge that would be recognized (or, for services furnished on or after January 1, 1992, the fee schedule amount provided under section 1848) if the services had been performed by an anesthesiologist, or the fee schedule for such services established by the Secretary in accordance with subsection (l), (I) with respect to covered items (described in section 1834(a)(13)), the amounts paid shall be the amounts described in section 1834(a)(1), and(J) with respect to expenses incurred for radiologist services (as defined in section 1834(b)(6)), subject to section 1848, the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount provided under the fee schedule established under section 1834(b), (K) with respect to certified nurse-midwife services under section 1861(s)(2)(L), the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount determined by a fee schedule established by the Secretary for the purposes of this subparagraph (but in no event shall such fee schedule exceed 65 percent of the prevailing charge that would be allowed for the same service performed by a physician, or, for services furnished on or after January 1, 1992, 65 percent (or 100 percent for services furnished on or after January 1, 2011) of the fee schedule amount provided under section 1848 for the same service performed by a physician), (L) with respect to qualified psychologist services under section 1861(s)(2)(M), the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount determined by a fee schedule established by the Secretary for the purposes of this subparagraph, (M) with respect to prosthetic devices and orthotics and prosthetics (as defined in section 1834(h)(4)), the amounts paid shall be the amounts described in section 1834(h)(1), (N) with respect to expenses incurred for physicians' services (as defined in section 1848(j)(3)) other than personalized prevention plan services (as defined in section 1861(hhh)(1)), the amounts paid shall be 80 percent of the payment basis determined under section 1848(a)(1), (O) with respect to services described in section 1861(s)(2)(K) (relating to services furnished by physician assistants, nurse practitioners, or clinic nurse specialists), the amounts paid shall be equal to 80 percent of (i) the lesser of the actual charge or 85 percent of the fee schedule amount provided under section 1848, or (ii) in the case of services as an assistant at surgery, the lesser of the actual charge or 85 percent of the amount that would otherwise be recognized if performed by a physician who is serving as an assistant at surgery, (P) with respect to surgical dressings, the amounts paid shall be the amounts determined under section 1834(i), (Q) with respect to items or services for which fee schedules are established pursuant to section 1842(s), the amounts paid shall be 80 percent of the lesser of the actual charge or the fee schedule established in such section, (R) with respect to ambulance services, (i) the amounts paid shall be 80 percent of the lesser of the actual charge for the services or the amount determined by a fee schedule established by the Secretary under section 1834(l) and (ii) with respect to ambulance services described in section 1834(l)(8), the amounts paid shall be the amounts determined under section 1834(g) for outpatient critical access hospital services, (S)(i) except as provided in clause (ii),subject to subparagraph (EE), with respect todrugs and biologicals (including intravenous immune globulin (as defined in section 1861(zz))) not paid on a cost or prospective payment basis as otherwise provided in this part (other than items and services described in subparagraph (B)), the amounts paid shall be 80 percent of the lesser of the actual charge or the payment amount established in section 1842(o) (or, if applicable, under section 1847, 1847A, or 1847B), and(ii) with respect to insulin furnished on or after July 1, 2023, through an item of durable medical equipment covered under section 1861(n), the amounts paid shall be, subject to the fourth sentence of this subsection, 80 percent of the payment amount established under section 1847A (or section 1847B, if applicable) for such insulin, (T) with respect to medical nutrition therapy services (as defined in section 1861(vv)), the amount paid shall be 80 percent (or 100 percent if such services are recommended with a grade of A or B by the United States Preventive Services Task Force for any indication or population and are appropriate for the individual) of the lesser of the actual charge for the

Additional Views

My colleagues, cancer affects everyone. Today's mark-up represents a result of dedicated work towards one common goal: providing a coverage pathway for innovative cancer screenings. This mark-up is of the utmost importance given the impact cancer continues to have upon our closest colleagues. A late- stage cancer diagnosis stole our nation's champion and our dear, John Lewis. Cancer diagnosed in late stage stole Speaker Mike Johnson's 63-year-old father from him just 3 days before he was sworn in. Last Congress, our colleague, Sheila Jackson Lee shared her diagnosis of pancreatic cancer. This Congress, we have already lost three colleagues, Congressmen Slyvester Turner, Raul Grijalva, and Gerald Connolly to the battle of cancer. Cancer, indeed, knows no bounds. It can and does affect everyone. This fight against cancer is personal to me, a late-stage cancer diagnosis took the life of my mother--the namesake for this important legislation, Ms. Nancy Gardner Sewell. I want to thank our colleague Rep. Jodie Arrington for being a co- champion of this bill and for surprising and honoring me in naming the bill after my mother, Nancy Gardner Sewell. Who was she? My mom was: A devout Christian who lived a life of faith. An exemplary educator and librarian-media specialist. She served in the Selma schools for 36 years, where she shaped minds and lifted up children. As a librarian, she was a strong advocate of reading and a champion of literacy initiating the Reading is Fundamental (RIF) program in 1973 delivering books to children throughout Alabama, Mississippi and Tennessee. A program that still serves the kids in Selma-Dallas County and Alabama's rural blackbelt. Nancy Sewell was a trailblazing civic leader. She became the first African American woman elected to Selma's City Council and served as an inspirational role model for women in politics. Her favorite saying was ``Bloom where you are planted''. You can make a difference right where you are. And she made a big difference in the lives of the many people she touched. My mother believed in community. She believed that knowledge mattered. She believed that no one should be left behind--she strove to build bridges and tear down walls of injustice. Her life's work was about service, about caring, about making sure people had what they needed to flourish. My Mom represents one of the millions of people who have lost their battle to cancer, and my personal story represents one of the millions of loved ones who have had to endure such a horrible loss. It is our duty to do whatever we can to rid this nation of the scourge of cancer by giving coverage and access to the most vulnerable in our society. Therefore, I hope you will join me in supporting H.R. 842 the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. Currently, this bill has overwhelming bipartisan support in both chambers of Congress! 295 of our colleagues in the House of Representatives, and 62 in the Senate have signed on to cosponsor this legislation since its introduction in February! I am also overwhelmed by the support this bill has earned from cancer advocacy groups-- such as the American Cancer Society Cancer Action Network, the Prevent Cancer Foundation, the National Minority Quality Forum, The Association of Community Cancer Centers, Cancer Support Community, Fight Colorectal Cancer, Go2 for Lung Cancer, The National Grange, the Ovarian Cancer Research Alliance, and more than 600 advocacy organizations across the country which include more than a dozen organizations in my home state of Alabama! Mr. Chairman, I would like to acknowledge and thank the patient advocates attending today's markup. I request unanimous consent to enter the 2025 letter of support from the Prevent Cancer Foundation listing every nationwide endorsing organizations of this legislation. Like so many Americans, my mother received her diagnosis of pancreatic cancer after the cancer had already spread, making it harder to treat. New cancer screening tools have the potential to change this. Multi-cancer early detection tests can screen for dozens of cancers--such as pancreatic--for which we have not previously been able to screen. This means we can catch more cancers in their earlier stages, giving patients their best chance at beating the disease. This year, more than 600,000 Americans will die from cancer. This number could easily be reduced with early detection tools! 66 is the median age for receiving a cancer diagnosis in the United States. This legislation serves to provide our seniors the opportunity to fight cancer earlier when it is less deadly. When there are steps we can take to reduce the suffering associated with cancer, it is our responsibility to do so. For Congress today this means ensuring Americans have access to the most effective tools to help combat the disease. Medicare laws do not currently provide timely coverage of these technologies. It is our job to proactively ensure accessibility for those who need it most. We must step in and create a pathway for coverage and access for early detection tests. That is exactly what the MCED bill does. Like similar legislation we have passed that create coverage pathways and access for mammography and colorectal screenings. This legislation will drive value in Medicare by reducing the significant costs attributed to advanced cancer care, and more importantly, it will save lives. I am so thankful for the support this bill has received, both in Congress and amongst the cancer community. This bill passed unanimously out of this committee last Congress, and I pray we do so again today! Our work is not done until this bill becomes law. Millions of Americans are counting on us. Thank you. Terri A. Sewell. SUPPLEMENTAL VIEWS H.R. 842 adds multi-cancer early detection (MCED) screening tests as a covered benefit under Medicare, effective January 1, 2029. MCED tests have the potential to concurrently detect multiple cancer types across multiple organ sites. The legislation requires that an MCED test must be cleared under section 510(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Medicare coverage. Under the Amendment in the Nature of a Substitute (ANS) reported out, Medicare can only pay for one test per year for an individual over 50 years of age and under 65 in 2029 (under 65 of age increases by one year for each succeeding year of coverage, so under 66 in 2030 and so on). Despite this inequitable approach, the bill importantly allows the Secretary to ensure coverage is tailored to patient needs once the clinical evidence is available. Once the tests are recommended by a grade of A or B by the United States Preventive Services Task Force (USPSTF), they will be covered as a preventive service through Medicare's traditional preventive services coverage pathway, and the bill's prescribed age and frequency limitations would not apply but would instead follow the USPSTF recommendations. The original bill did not limit access to MCED screenings on the basis of age. While Democrats strongly support ensuring access to cancer screenings and unanimously supported the legislation in Committee, it is preferable to not base the determination of access to these MCED screening on an arbitrary age. Meanwhile, Republicans have actively tried to restrict access to needed, evidence-based care, while decimating the very research infrastructure necessary to bring new scientific innovations to market. Over the last nine months, the Trump Administration has slashed nationwide National Institutes of Health (NIH) funding, terminating hundreds of scientific grants. This rapid disinvestment in scientific research endangers patient care, jobs and the economy and threatens America's world leadership in health care innovation and cures. CBO recently reported that cuts to the Food and Drug Administration FDA and National Institutes of Health (NIH) will hinder the development of new drugs.\1\ Specifically, cuts resulting in a nine-month increase in FDA review times cuts to preclinical NIH funding will result in 53 fewer newer prescription drugs over the next three decades. --------------------------------------------------------------------------- \1\https://www.cbo.gov/system/files/2025-07/61373-Drugs.pdf. --------------------------------------------------------------------------- The world's largest public funder of biomedical research, the NIH drives discoveries that lead to life-saving therapies and generates economic growth. NIH funding spurred an estimated $92.89 billion in economic activity in Fiscal Year (FY) 2023 alone. For every $100 million of funding, NIH-supported research generates 76 patents, which create opportunities for an estimated $598 million in further research and development.\2\ In FY 2023 alone, NIH awarded $37.81 billion in research funding across all 50 states and Washington, D.C., supporting 412,041 jobs.\3\ --------------------------------------------------------------------------- \2\https://www.nih.gov/about-nih/what-we-do/impact-nih-research/ serving-society/direct-econom ic-contributions. \3\https://www.unitedformedicalresearch.org/wp-content/uploads/ 2024/03/UMR-NIHs-Role-in-Sustaining-the-US-Economy-2024-Update.pdf. The Trump Administration has terminated hundreds--possibly thousands--of NIH grants for scientific research.\4\ These cuts threaten U.S. leadership in medical research, allowing countries like China to expand their investments in biomedical re- search and surpass the U.S. in developing future treatments and cures.\5\ Leading specialty medical societies have raised the alarm bells: --------------------------------------------------------------------------- \4\https://taggs.hhs.gov/Content/Data/HHS_Grants_Terminated.pdf. \5\Government of China, (2022), 14th Five-Year Plan for Bioeconomy Development, https://leap.unep.org/en/countries/cn/national- legislation/14th-five-year-plan-bioeconomy-development. The very research that drives medical advancements, fuels economic growth, and sustains America's competitive edge will suffer--not because of a lack of talent or opportunity but because of an arbitrary policy that undermines the financial sustainability of research institutions . . . This policy shift would undermine America's biomedical leadership, erode its workforce competitiveness, and threaten national security, ultimately ceding scientific and technological dominance to global competitors.\6\ --------------------------------------------------------------------------- \6\https://www.aans.org/wp-content/uploads/2025/03/Physician- Response-to-NIH-Indirect-Cost-Policy-2025-03-05-final.pdf. Trump Administration policies are threatening clinical trials that patients and families depend on to access to therapies, including cancer prevention and treatment. Researchers may be forced to halt clinical trials abruptly, leaving patients and physicians without other options.\7\ A letter from thousands of patients with rare diseases notes: --------------------------------------------------------------------------- \7\https://www.theatlantic.com/health/archive/2025/03/trump-nih- clinical-trials-patient-safey/682217/. --The removal of key experts at Health and Human Services Agencies, including NIH, FDA [Food and Drug Administration], and CDC [Centers for Disease Control and Prevention]--paired with recent executive orders on federal funding and communications, compromises our nation's economic prosperity and threatens the foundation that enables hope. For children and adults with rare diseases, even a momentary pause in funding for these programs and agencies will have devastating, life-altering consequences.\8\ --------------------------------------------------------------------------- \8\https://everylifefoundation.quorum.us/campaign/111750/. Furthermore, cutting funding to U.S research institutions and medical centers will deprive all families of new treatments and medical breakthroughs. Attorneys General from 22 states sued the Trump Administration, the Department of Health and Human Services (HHS), and the NIH for unlawfully cutting funds that support cutting-edge medical and public health research at universities and research institutions across the country.\9\ --------------------------------------------------------------------------- \9\https://www.mass.gov/news/ag-campbell-sues-trump-administration- for-defunding-medical-and-public-health-innovation-research. The war on ``Diversity, Equity, and Inclusion'' harms product development and scientific knowledge. In March, in an unprecedented move, the NIH abruptly terminated millions of dollars of research awards to scientists related to diversity, equity, and inclusion, in violation of court orders from federal judges, effectively imposing conditions on funding that did not exist at the time the grants were awarded.\10\ --------------------------------------------------------------------------- \10\https://www.bostonglobe.com/2025/03/06/metro/trump-kills- science-funding-dei/. By terminating programs that ensure robust participation in clinical trials, the Trump Administration is attempting to illegally block companies from complying with clinical trial requirements set by Congress to ensure new therapies have complete information on how they work for all Americans when they come to market. Congress requires drug and device companies to develop diversity plans, which will ultimately enable them to enroll more diverse patient populations in clinical trials and ensure representation of populations, who will use the medical products once approved.\11\ Diverse representation in clinical trials is a scientific necessity. For example, cancer research has shown that the effectiveness of certain treatments can vary based on genetic or ethnic backgrounds, making diverse enrollment critical.\12\ --------------------------------------------------------------------------- \11\https://www.fda.gov/regulatory-information/selected-amendments- fdc-act/food-and-drug- omnibus-reform-act-fdora-2022. \12\https://www.cancer.gov/research/infrastructure/clinical-trials/ nci-supported/nci-match::text= NCI%2DMATCH%2C%20also%20known%20as,no%20matter%20the%20cancer%20type. Rolling back programs that ensure clinical trials and other research are representative of the U.S. at large will not only make it harder to recruit a broad array of study participants-- which is a setback for science--but it will also reverse --------------------------------------------------------------------------- decades of progress in reducing disparities in health outcomes. The unprecedented levels of HHS cuts will hinder development, approval, and access to drugs, including biosimilars, potentially increasing risk to patient health and safety. This administration indiscriminately and almost immediately fired thousands of federal workers, including those that oversee medical device safety, food safety, and clinical trials, which will slow innovation and affect the safety and availability of consumer products--including food, drugs, and devices--as well as responses to public health threats, such as influenza, measles, and other infectious disease outbreaks.\13\\14\\15\ Specifically: --------------------------------------------------------------------------- \13\https://abcnews.go.com/US/agencies-federal-workers-fired/ story?id=118901289. \14\https://www.nytimes.com/2025/02/18/us/politics/fda-cdc-health- department-trump.html. \15\https://www.msn.com/en-us/health/other/cdc-invites-back-about- 180-fired-employees-includ ing-some-who-help-fight-outbreaks/ar- AA1Ak2VV?ocid=BingNewsSerp. Sweeping cuts at the NIH will hinder the world's largest funder of biomedical research in the nation's development of new drugs. These cuts currently stand at six percent of NIH's workforce and include the parts of NIH responsible for decisions regarding what diseases to study and medicines to develop.\16\ --------------------------------------------------------------------------- \16\Megan Molteni, et al., Five NIH Institute Directors and Numerous Lab Heads Ousted in Unprecedented Shake-Up, STAT (April 1, 2025), https://www.statnews.com/2025/04/01/nih-rif-1200-layoffs-raise- concerns-health-medicine-biomedical-research/ (last visited April 2, 2025). Drastic cuts totaling 19 percent of the Food and Drug Administration (FDA) budget will compromise the agency's ability to approve new biosimilars and ensure their safety. This rollback will erode the agency's core functions, including monitoring drug safety, and evaluating and approving new drugs, devices, and vaccines.\17\ Without qualified staff to review drug applications and inspect new manufacturing facilities, patients cannot safely access these drugs. --------------------------------------------------------------------------- \17\Lizzy Lawrence and Sarah Todd, FDA Commissioner Marty Makary Gets Off to a Brusing Start as Agency Is Wracked by Layoffs, STAT (April 1, 2025), https://www.statnews.com/2025/04/01/fda-rif-3500- layoff-notices-under-rfk-jr-hhs-reorganization/ (last visited April 2, 2025). Staffing cuts at the CDC will affect the monitoring of emerging disease and public health threats. Republicans have put their extremist views ahead of finding a cure for cancer. President Biden's Cancer Moonshot initiative sought to accelerate development of cures for cancer. It was the largest organized effort ever by the federal government to accelerate cancer research, find cures, and reduce cancer deaths by half within 30 years--and the nearly $2 billion investment received bipartisan support and praise. The program was funded on a bipartisan basis in the 21st Century Cures Act.\18\ Unfortunately, Republicans zeroed out funding for the Cancer Moonshot in March of 2024.\19\ --------------------------------------------------------------------------- \18\https://www.congress.gov/bill/114th-congress/house-bill/34. \19\https://www.politico.com/news/2024/04/29/congress-is-killing- bidens-cancer-moonshot-00154718. Currently, the FDA has cleared, classified, or approved no MCED tests, and research is ongoing to understand the benefits of using MCED tests in routine clinical practice. MCED tests aim to detect many types of cancer early using noninvasive methods like blood tests, which could lead to earlier treatment. However, early detection does not always improve the chance of a cure or extend life for some cancers.\20\ Follow-up tests are needed to confirm a diagnosis, and research has shown that more than half the time, no cancer could be found in people who had a positive MCED test.\21\ Clinical trial data will be critical to determine whether detection with MCED tests improves outcomes such as cancer-related survival.\22\\23\\24\ This

Source: https://api.congress.gov/v3/committee-report/119/hrpt/333